Generium Launches First Biosimilar of Dornase Alfa Utilizing Selexis’ SUREtechnology Platform

 Generium Launches First Biosimilar of Dornase Alfa Utilizing Selexis’ SUREtechnology Platform

Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hemolytic Uremic Syndrome (aHUS) in Russia

Shots:

  • Generium is the first company to develop biosimilar of Dornase Alfa which received approval as an inhalation solution to be used together with antibiotics, bronchodilators, and steroids for controlling symptoms of cystic fibrosis
  • The biosimilar of Dornase Alfa is the sixth product to be approved utilizing Selexis’ SUREtechnology Platform and will be available to maintain the QoL in patients with cystic fibrosis
  • Selexis’ SUREtechnology Platform is based on Selexis Genetic Elements, a novel human DNA based elements controlling the dynamic organization of chromatin across mammalian cells and improves the way cells are used in the discovery, development and manufacturing of recombinant proteins

Click here to­ read full press release/ article | Ref: Selexis | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post